Cargando…
Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
INTRODUCTION: Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to increasing calls for multimodal and non-opioid pain...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648827/ https://www.ncbi.nlm.nih.gov/pubmed/32737803 http://dx.doi.org/10.1007/s40122-020-00189-x |